SuperworthDNA X SONM
- Market cap
- $4.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
DNA X's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $27.6M+35% | $13.4M−44% | $16.8M−35% | $11.5M−57% | $15M−46% | $15M+12% | $16.7M−0% | $11.2M−3% | $16.2M+8% | n/a | n/a | n/a | |
| Cost of revenue | $22M+28% | $8.3M−59% | $13.9M−36% | $8.5M−62% | $10.8M−51% | $15.2M+83% | $8.4M−40% | $10.3M+21% | $14.4M+33% | n/a | n/a | n/a |
| Gross profit | $5.6M+69% | $5.1M+30% | $2.9M−31% | $3M−33% | $4.2M−25% | −$183K | $8.4M+188% | $845K−72% | $1.8M−57% | n/a | n/a | n/a |
| R&D | $741K | $926K−24% | $456K+334% | $557K | $715K−4% | $12.5M+1251% | $1.6M+258% | $909K+63% | $181K−75% | n/a | n/a | n/a |
| SG&A | $4.2M−22% | $5.4M+45% | $5.1M+37% | $5.7M+54% | $5.9M+41% | $8.7M+59% | $870K−83% | $1.5M−74% | $5.6M−5% | n/a | $3.6M+316% | $1.3M−13% |
| $688K | −$1.3M+19% | −$2.7M | −$6.5M | −$2.4M | −$22.1M+1661% | −$870K−68% | −$1.5M−77% | −$4M+68% | n/a | −$3.6M+316% | −$1.3M−13% | |
| Interest expense | $2K | $8K−65% | n/a | $17K+240% | n/a | n/a | $71K | $389K+2188% | $339K | n/a | $131K+85% | $140K−64% |
| Pre-tax income | $623K | −$1.3M+19% | −$2.8M | −$6.6M | −$2.4M | −$21.7M+1620% | −$961K−65% | −$1.9M−72% | −$4.7M+95% | n/a | −$3.9M+309% | −$1.2M−33% |
| $96K+33% | $93K | $125K+11% | $37K−49% | $117K+22% | −$53K | $132K+6% | $139K+276% | $90K−23% | n/a | n/a | n/a | |
| Net income | $527K | −$1.4M+30% | −$2.9M | −$6.6M | −$2.5M | −$21.6M+1498% | $458K | −$7.5M+13% | −$4.8M+89% | −$8.9M−59% | $6.3M+1284% | −$1.2M−83% |
| $2.16 | −$5.58+3% | −$11.70 | −$25.38 | −$9.32 | −$79.45+1324% | $1.41 | −$14.15−44% | −$4.83−48% | −$8.53−89% | $5.01+255% | −$0.92−94% | |
| 245.4K+22% | 245.1K+8% | 246.6K+8% | 260.3K+5% | 269.4K+10% | 272K+11% | 324.4K+32% | 528.4K+103% | 984.9K+266% | 1M+283% | 1.3M+290% | 1.4M+156% |
EPS, diluted: 8 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Technology nearest DNA X's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SONMDNA X | $4.6M | n/m | n/a | n/m | n/m | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| FIEEFiEE | $26.9M | 9.3× | 102× | n/m | n/m | n/m | |
| NSYSNortech Systems | $29.4M | 27.8× | 13.3× | 0.2× | +6% | 0.8% | |
| Peer median | $26.9M | 11.4× | 13.3× | 0.9× | +42% | 8.5% |
More on DNA X
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Communication Equipment
- Sector
- Technology
Valuation data, not investment advice. Prices as of .